Andrea is the US Account Executive at Alithea Genomics, based in Boston, MA. In this role, she works closely with clients across North America, empowering their research with cutting-edge DRUG-seq and BRB-seq high-throughput transcriptomic platforms. Previously, she was the Technology Platform Lead for DRUG-seq at Novartis Biomedical Research in Cambridge, MA, advancing functional genomic screens and transcriptomic solutions for multidisciplinary projects. Andrea also completed her postdoctoral fellowship at Novartis, focusing on high throughput and high content imaging screens for lysosomal storage and neuronal diseases. She previously earned her PhD in Biochemistry and Molecular Biology from UCLA and a Bachelor’s degree from UMass Amherst.